COMBINATIONS OF ANTI-OESTROGEN COMPOUNDS AND PKC MODULATORS AND THEIR USE IN CANCER THERAPY

摘要

Products containing an anti-oestrogen compound and a PKC modulator or activator as a combined preparation simultaneous, separate or sequential use in cancer therapy are provided. The PKC modulator or activator may be a bryostatin or a neristatin obtainable fron the organism Bugula neritina, and the anti-oestrogen compound may be tamoxifen or a triphenylalkene derivative having anti-oestrogen activity, or a steroid derivative having anti-oestrogen activity.